论文部分内容阅读
目的观察左西孟旦及重组人脑利钠肽联合治疗急性心肌梗死合并心功能不全的临床疗效。方法选择急性心肌梗死合并左心功能不全的患者共68例,随机分为:A组(治疗组)35例,予左西孟旦及重组人脑利钠肽联合静点,B组(对照组)33例,予常规硝普钠,多巴酚丁胺等药物静点治疗。对两组患者临床疗效。对比观察两组患者入院时及治疗1周后NTpro-BNP及超声心动图左室射血分数变化情况,评价呼吸困难改善情况。结果左室射血分数A组明显高于B组,NTpro-BNP A组明显低于B组,A组呼吸困难评分明显低于B组,均有统计学差异(P<0.05)。结论联合静点左西孟旦及重组人脑利钠肽可以显著提高急性心肌梗死合并心功能不全的临床疗效。
Objective To observe the clinical efficacy of levosimendan combined with recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction complicated with cardiac insufficiency. Methods A total of 68 patients with acute myocardial infarction complicated with left ventricular dysfunction were randomly divided into A group (treatment group) 35 cases, levosimendan and recombinant human brain natriuretic peptide combined with static point, group B (control group ) 33 cases, to conventional sodium nitroprusside, dobutamine and other drugs static treatment. Clinical efficacy of two groups of patients. The changes of NTpro-BNP and echocardiography left ventricular ejection fraction were compared between two groups after admission and one week after treatment to evaluate the improvement of dyspnea. Results The left ventricular ejection fraction in group A was significantly higher than that in group B, and the level of NTpro-BNP A in group A was significantly lower than that in group B. The score of dyspnea in group A was significantly lower than that in group B (P <0.05). Conclusions The combination of levosimendan and recombinant human brain natriuretic peptide can significantly improve the clinical efficacy of acute myocardial infarction with cardiac dysfunction.